4月24日，生物科技公司康方生物在港交所主板成功上市，共募集约25.8亿港元资金。通商律师事务所、美迈斯律师事务所担任发行人律师，天元律师事务所、达维律师事务所则担任联席保荐人及包销商法律顾问。

根据通商的一份新闻稿，康方生物是截至目前第16家未有盈利的港交所上市生物科技公司，这也是2020年截至目前募资规模最大的港股上市项目。

成立于2012年，总部设立于广东省中山市，康方生物是一家处于临床阶段的生物制药公司，致力于自主发现、开发及商业化首创及同类最佳疗法，专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。

根据路透社报道，康方生物的招股书在今年2月初曾因“未符合监管要求”被退回，这也是公司在完善招股书财务数据后第二次申请上市。

摩根士丹利和摩根大通担任联席保荐人，Campbells律师事务所则就开曼群岛法律为发行人提供意见。

达维团队项目牵头律师为合伙人何鲤、褚洋；Campbells团队牵头律师为合伙人、中国部主管聂淑娴。

C&F, OMM, Tian Yuan, Davis Polk on Akeso’s $312 mln HK IPO

Commerce & Finance Law Offices and O’ Melveny & Myers have advised China biotech company Akeso on its $312 million initial public offering in Hong Kong, with Tian Yuan Law Firm and Davis Polk & Wardwell acting for the joint sponsors.

According to Commerce & Finance, Akeso is the sixteenth unprofitable biotech company to be listed on the Hong Kong Stock Exchange, and this is by far the biggest Hong Kong initial public offering in 2020.

Founded in 2012 and headquartered in Zhongshan, Guangdong province, Akeso is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. It is dedicated to meeting medical needs in oncology, immunology and other therapeutic areas.

According to Reuters, Akeso’s previous filing attempt was sent back by HKEX for not meeting the correct regulatory requirements in this February.

JPMorgan and Morgan Stanley acted as joint sponsors in the deal, and Campbells provided offshore legal advice to the issuer.

The Davis Polk team was led by partners He Li and Chu Yang; meanwhile the Campbells team was led by partner and head of PRC group Jenny Nip.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.